FDCP
RPRX icon

Foster Dykema Cabot & Partners’s Royalty Pharma RPRX Stock Holding History

Foster Dykema Cabot & Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-121
Closed -$3.42K – 464
2024
Q3 		$3.42K Buy
+121
New +$3.35K ﹤0.01% 425

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Foster Dykema Cabot & Partners's RPRX Position: Q4 2024 in Review

Foster Dykema Cabot & Partners sold out of Royalty Pharma (RPRX) in Q4 2024, closing a stake of 121 shares — an estimated $3.42K sold.

Foster Dykema Cabot & Partners first reported a position in RPRX in Q3 2024 and held it in 1 quarter. The position peaked at $3.42K in Q3 2024. 416 funds tracked by Wall St. Rank hold RPRX as of Q4 2024.

  • Foster Dykema Cabot & Partners reported no remaining Royalty Pharma position as of Q4 2024 after selling out during the quarter.
  • Foster Dykema Cabot & Partners sold 121 Royalty Pharma shares in Q4 2024, an estimated $3.42K.
  • Foster Dykema Cabot & Partners first reported a position in Royalty Pharma in Q3 2024 and held it in 1 quarter.
  • Foster Dykema Cabot & Partners's Royalty Pharma position peaked at $3.42K in Q3 2024.
  • 416 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2024.

Based on Foster Dykema Cabot & Partners's 13F filing for Q4 2024, filed 13 Feb 2025.